Qlucore starts project after receiving prestigious EU grant to advance personalized cancer treatment

- EIC grant awarded after fierce competition

Qlucore, a leader in software development for precision cancer diagnostics, has passed the evaluation phase and will receive a prestigious EIC Accelerator grant of 2,5 million Euros to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer. In March the grant was made public and Qlucore is now starting the project and has received the first payment.

During the project Qlucore will develop and launch CE-marked software for clinical cancer diagnostics for the two cancer types. The project will stretch over three years, with objectives to develop solutions for use by clinical laboratories as well as companion diagnostics (CDx) solutions in collaboration with pharma companies.
 
The selected cancer disease areas are especially suited to the solutions as both cancer types have multiple changes on RNA level that can be utilized to improve diagnosis and treatment. Currently this information is not fully used to provide the right therapy for the right patient. The aim of the project is to change this.
 
“The recognition from the expert review panels of our solutions and the addressed clinical need is a great endorsement of our strategic direction and focus on RNA-based solutions. RNA-based solutions are gaining momentum, allowing for cancer classification using gene fusions and gene expression signatures”, says Carl-Johan Ivarsson, CEO of Qlucore
 
For a medical device to be used in healthcare diagnostics, IVDR regulations require the device to have CE marking. For this project Qlucore will build on the significant investments in its solutions for acute lymphoblastic leukemia, Qlucore Diagnostics BCP-ALL, both from a software technical point of view and from a quality management system (QMS) point of view
 
"Receiving this grant in the company of tough competition further endorses our position at the forefront of RNA-seq based modern clinical diagnostics. This award will strengthen Qlucore financially as well as in the market", says Carl-Johan Ivarsson, CEO of Qlucore.
 
Intended customers are clinical laboratories in Europe in the first phase and the US market in a second phase. Qlucore is looking to use the solution in parallel for companion diagnostics (CDx) together with pharma companies.